Last reviewed 2026-05-30 · How we verify

Testosterone and standard NMES

VA Office of Research and Development · Phase 2 active Small molecule ✓ Verified May 2026

Testosterone and standard NMES is a Small molecule drug developed by VA Office of Research and Development. It is currently in Phase 2 development. Also known as: Testosterone and neuromuscular electrical stimulation.

Testosterone is a small molecule androgen receptor agonist that has been studied in clinical trials for conditions such as Spinal Cord Injury. It has been used in combination with standard Neuromuscular Electrical Stimulation (NMES) in research studies to investigate its effects on denervated muscles after spinal cord injury.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Testosterone and standard NMES
Also known as	Testosterone and neuromuscular electrical stimulation
Sponsor	VA Office of Research and Development
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Testosterone and Long Pulse Stimulation After SCI (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Testosterone and standard NMES CI brief — competitive landscape report
Testosterone and standard NMES updates RSS · CI watch RSS
VA Office of Research and Development portfolio CI

Frequently asked questions about Testosterone and standard NMES

What is Testosterone and standard NMES?

Testosterone and standard NMES is a Small molecule drug developed by VA Office of Research and Development.

Who makes Testosterone and standard NMES?

Testosterone and standard NMES is developed by VA Office of Research and Development (see full VA Office of Research and Development pipeline at /company/va-office-of-research-and-development).

Is Testosterone and standard NMES also known as anything else?

Testosterone and standard NMES is also known as Testosterone and neuromuscular electrical stimulation.

What development phase is Testosterone and standard NMES in?

Testosterone and standard NMES is in Phase 2.

Manufacturer: VA Office of Research and Development — full pipeline
Also known as: Testosterone and neuromuscular electrical stimulation

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing